<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DB385944-AAE4-4D5E-9280-AE37FD29CF3F"><gtr:id>DB385944-AAE4-4D5E-9280-AE37FD29CF3F</gtr:id><gtr:name>AveXis, Inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1D963404-E8A7-4202-9456-1FF57DBB985B"><gtr:id>1D963404-E8A7-4202-9456-1FF57DBB985B</gtr:id><gtr:name>UCL Cancer Institute</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:department>Neurosciences</gtr:department><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DB385944-AAE4-4D5E-9280-AE37FD29CF3F"><gtr:id>DB385944-AAE4-4D5E-9280-AE37FD29CF3F</gtr:id><gtr:name>AveXis, Inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1D963404-E8A7-4202-9456-1FF57DBB985B"><gtr:id>1D963404-E8A7-4202-9456-1FF57DBB985B</gtr:id><gtr:name>UCL Cancer Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6D96679F-7B87-4095-8643-EDEC89A16D03"><gtr:id>6D96679F-7B87-4095-8643-EDEC89A16D03</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:otherNames>Geoffrey</gtr:otherNames><gtr:surname>Ince</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E3406FFA-68B6-49BB-A34C-5A9008DA9B5A"><gtr:id>E3406FFA-68B6-49BB-A34C-5A9008DA9B5A</gtr:id><gtr:firstName>Pamela</gtr:firstName><gtr:otherNames>Jean</gtr:otherNames><gtr:surname>Shaw</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F7BF55C1-D08C-44E6-B66D-DAE7B73E9820"><gtr:id>F7BF55C1-D08C-44E6-B66D-DAE7B73E9820</gtr:id><gtr:firstName>Mimoun</gtr:firstName><gtr:surname>Azzouz</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/322B0287-D86B-44B3-9A53-10FFA0F9C9DF"><gtr:id>322B0287-D86B-44B3-9A53-10FFA0F9C9DF</gtr:id><gtr:firstName>Ke</gtr:firstName><gtr:surname>Ning</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1001492"><gtr:id>91C401CE-EC5A-4A3F-9DE0-EF2EDA8F8F52</gtr:id><gtr:title>SMN Replacement Therapy for Spinal Muscular Atrophy: Clinical Development</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001492</gtr:grantReference><gtr:abstractText>SMA is due to premature death of motor neurons which are connected to muscle, and provide the stimulus to initiate muscle contraction. The disease is caused by depletion in the SMN protein levels. We recently showed that genetically modified viruses, making them safe to use in human, can be successfully used to restore the level of SMN both in cells and in a mouse model. The latest experiments showed for the first time that we can replace the SMN gene, reverse the symptoms leading to a dramatic effect on survival in the SMA mouse model. However, further in vivo studies are needed to characterise our strategy before entering clinical application in human. Our major goals are: 1) Optimise a method to produce large quantity of clinical grade vector; 2) select the appropriate dose for further safety studies in rodents; 3) Evaluate the safety and toxicity of our system. These studies represent an important and necessary step towards translation into human treatment.</gtr:abstractText><gtr:technicalSummary>Spinal muscular atrophy is caused by mutations of the survival motor neuron (SMN) gene. Gene therapy aimed at restoring the SMN protein expression represents therefore a rationale therapeutic approach to ameliorate the disease phenotype. We recently showed that a gene transfer of self complementary adeno-associated virus serotype 9 expressing a codon optimised version of SMN in SMNdelta7 mice leads to complete correction of the motor deficits in these animals resulting in a substantial extension in their life span. These data provide evidence for the most efficacious therapy observed in this field to date. Our ultimate goal is to progress the SMN replacement approach to a phase I clinical trial in SMA patients. However, progress is limited by the requirement for further pivotal pre-clinical studies and vector production scaling up. The proposed pre-clinical studies will provide essential information about safety and suitability of our vector system for clinical application.</gtr:technicalSummary><gtr:fund><gtr:end>2016-10-02</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-03</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>740248</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AveXis, Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>MICA with AveXis to develop gene therapy for SMA</gtr:description><gtr:id>C07BBC5A-D39F-4316-A557-24EA367EA8B9</gtr:id><gtr:impact>This collaboration just started and we expect that our partnership with AveXis will facilitate and help achieving our final milestone of this project</gtr:impact><gtr:partnerContribution>AveXis holds the exclusive worldwide licence for the AAV9 vector (ChariSMA), the essential carrier to deliver genes to motor neurons. This collaboration will benefit both partners: 1) AveXis has formal clearance from the FDA to begin a trial and has already begun the clinical program. Experience with US regulators will advance the rapid filing for CTA in the EU. AveXis will provide a non-exclusive research licence for access to and use all of their data generated in the USA; 2) Sheffield will make all steps to enable this project to move forward with an appropriate GLP TOX study in UK/EU. 3) Sheffield and AveXis will work together to secure funds required for future clinical studies in UK/EU.</gtr:partnerContribution><gtr:piContribution>Prof Azzouz has extensive pre-clinical development expertise and has been developing gene therapy for SMN replacement for over 10 years, demonstrating proof of concept of the therapy in a SMA mouse model. Our goal is to develop gene therapy approach for SMN gene replacement in Spinal Muscular Atrophy. The aim is to develop GMP like vector for GLP toxicology and biodistribution studies in preparation for clinical trials in UK/EU</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCL Cancer Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Gene Therapy Consortium</gtr:department><gtr:description>AAV9 vector manufacturing</gtr:description><gtr:id>B59D9E78-99CD-47AA-8773-0DE7151FE6BF</gtr:id><gtr:impact>- Neuroscience
- Gene therapy
- Clinical development</gtr:impact><gtr:partnerContribution>Optimisation and set up of a protocol for AAV9 vector production that can be used for GMP clinical vector production</gtr:partnerContribution><gtr:piContribution>Generated proof-of-concept leading to the Award G1001492. 
Working towards preparing the program for clinical trials in SMA patients</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Open day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>25F3CBCC-64D2-479A-B491-099575B9FACC</gtr:id><gtr:impact>over 100 people attended the open days.
Talk followed by questions and discussions. Queries by e-mails and phone calls

patients (both adult and children) asked to visit the labs and talk to researchers</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentations by members of the team at the local branch of Motor Neuron Disease Association</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>3C96FE5F-46D1-4465-9FC3-3E47C531E0CD</gtr:id><gtr:impact>Local branch of Motor Neuron Disease Association requested that we attend one of their meetings and give presentations explaining our research work.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>149000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>CRISPR-Cas9 gene therapy for C9ORF72 linked ALS</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:id>163969AA-A5A1-4F60-B033-6413071049F5</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2500000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:description>ERC Advanced Investigator Award</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>European Research Council (ERC)</gtr:fundingOrg><gtr:id>B979819A-1526-4629-8D8C-7BD1E28C9C7D</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Secured Orphan Drug Designation from European Medicine Agency for SMN gene therapy replacement in SMA</gtr:description><gtr:id>4CBEE5F7-FA2F-43A3-A017-B3A5D522F8CF</gtr:id><gtr:impact>N/A</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:protection>Protection not required</gtr:protection><gtr:title>Orphan Drug Designation</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Impact of prenatal screening for therapy development in SMA</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>F15E9031-D15B-4B16-B87C-760509CDAB75</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>IMI workshops: Mechanisms to promote and progress advanced therapies to clinic and commercialisations</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>AB6A332C-36A6-44D4-94D6-F7AB66E32201</gtr:id><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">G1001492</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>